Aberration of the mTOR pathway occurs in numerous pediatric cancers as a result of gain‐of‐function mutations in oncogenes and/or loss‐of‐function mutations in tumor suppressors, which results in tumor growth, angiogenesis, evading cell death, and metastasis [1, 2, 3, 4, 5, 6, 7]. This evidence concerns the gene MTOR and neoplasm.